A5044151546- Diabetes Management and Research
- Diabetes Treatment and Management
- Cancer, Hypoxia, and Metabolism
- Birth, Development, and Health
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Metabolism and Genetic Disorders
Sanofi (South Korea)
2022-2024
The TOujeo BEyond glucose control (TOBE) study evaluated clinical outcomes with insulin glargine 300 units/mL (Gla-300) in insulin-naïve Korean people type 2 diabetes mellitus (T2DM) a real-world setting. This 24-week, prospective, non-interventional, multicenter, open-label, single-arm, observational included adults aged ≥ 20 years T2DM suboptimally controlled oral hypoglycemic agents and/or glucagon-like peptide 1 receptor agonists who require basal insulin. Eligible participants were...
Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and effectiveness of RAIs patients with type 2 diabetes mellitus (T2DM).This non-interventional, observational enrolled (aged >18 years) T2DM who were prescribed RAIs. The RAI analogs evaluated over 6 months.A total 299/451 analyzed. Approximately 90% (n/N=270/299) received insulin glulisine, which significantly reduced levels glycated...